At present, dabrafenib combined with trametinib has received Food and Drug Administration (FDA) approval for several indications, encompassing first-line treatment of BRAF V600E metastatic NSCLC, postoperative adjuvant treatment of BRAF V600E-mutated unresectable melanoma or metastatic melanoma harboring BRAF V600E mutation, locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, and children aged ≥1 year diagnosed with low-grade glioma (LGG) with BRAF V600E mutation. This evidence concerns the gene BRAF and low grade glioma.